Lupin recalls 26,352 bottles of Rifampin Capsules in US market

Lupin is recalling 26,352 bottles of Rifampin Capsules (300 mg), an antibiotic medication in the US market. The affected lot has been produced by the drug firm at its Aurangabad-based facility and marketed in the American market by its Baltimore-based unit Lupin Pharmaceuticals, Inc.
As per the US Food and Drug Administration (USFDA), the company is recalling the lot for being ‘Subpotent’. The company issued the Class II recall on March 21 this year.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.